SCHEMBL23244100

SCHEMBL23244100

O=C(Cc1ccccc1)N1CCN(c2ccc(O)cn2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ME2 P23368 14/20 1.00
▸ ME1 P48163 14/20 1.00
▸ ME3 Q16798 14/20 1.00
▸ KDM4E B2RXH2 2/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ HPGD P15428 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.53
▸ HDAC3 O15379 1/20 0.53
▸ HDAC4 P56524 1/20 0.53
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC7 Q8WUI4 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ HDAC10 Q969S8 1/20 0.53
▸ HDAC11 Q96DB2 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ HDAC9 Q9UKV0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23244336 0.87 ME2 (1.00) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL23972257 0.86 ME2 (0.75) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL23244406 0.85 ME2 (0.86) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL23244167 0.84 ME2 (0.84) ME2ME1ME3KDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL23244370 0.83 ME2 (0.83) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL26027590 0.83 ME2 (0.70) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL23682791 0.82 KDM4E (0.81) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL23244326 0.82 ME2 (0.70) ME2ME1ME3
SCHEMBL6350032 0.82 ME2 (0.70) ME2ME1ME3KDM4ESMN1; SMN2
SCHEMBL23259363 0.81 ME2 (0.67) ME2ME1ME3KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 — — US claimed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 — — WO claimed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 — — US claimed
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 — — US disclosed
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 — — US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 — — US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 — — US disclosed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 — — WO disclosed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 — — WO disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 — — US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 ME2 2/4885ME1 1/4885ME3 3/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 ME2 3/4885ME1 1/4885ME3 4/4885
US-20220127266-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 ME2 2/4885ME1 1/4885ME3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback